Pulse Biosciences (PLSE) Common Equity (2015 - 2025)

Pulse Biosciences' Common Equity history runs 11 years deep, the most recent figure standing at $80.7 million for Q4 2025.

• In Q4 2025, Common Equity fell 29.78% year-over-year to $80.7 million; the TTM figure through Dec 2025 stood at $80.7 million (down 29.78% YoY), while the FY2025 annual figure was $80.7 million, down 29.78% from the prior year.
• Common Equity was $80.7 million for Q4 2025 at Pulse Biosciences, down from $92.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $118.5 million in Q1 2025 to a low of -$10.7 million in Q1 2023.
• Historically, Common Equity has averaged $51.0 million across 5 years, with a median of $45.9 million in 2021.
• Biggest YoY gain for Common Equity was 2073.31% in 2023; the steepest drop was 151.29% in 2023.
• A 5-year view of Common Equity shows it stood at $44.4 million in 2021, then tumbled by 105.07% to -$2.2 million in 2022, then soared by 2073.31% to $44.4 million in 2023, then soared by 158.93% to $114.9 million in 2024, then slipped by 29.78% to $80.7 million in 2025.
• The last three Common Equity figures came in at $80.7 million (Q4 2025), $92.7 million (Q3 2025), and $104.5 million (Q2 2025), per Business Quant data.